Observational studyRheumatology international2025
High incidence of lymphoma in Sjögren's disease: predictors and mortality implications in a prospective cohort study.
Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unraveling the inflammatory bridge: genomic evidence identifies TNFRSF9 as a potential biomarker linking Sjögren's syndrome to total risk non-Hodgkin lymphoma.Clinical rheumatology · 2026Article
- Major adverse cardiovascular events in Sjögren's disease: incidence, associated factors, and impact on mortality in a prospective multicenter cohort.Rheumatology international · 2026Article
- Juvenile Sjögren disease: time for age-specific classification criteria.Pediatric rheumatology online journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
This study aimed to evaluate the standardized incidence ratios (SIRs) of non-Hodgkin lymphoma (NHL) in patients with Sjögren's disease (SjD) compared to the general population. Additionally, it sought to identify independent predictors of lymphoma and estimate both the relative risk (RR) and the etiologic fraction in exposed individuals (EFE) to assess the contribution of lymphoma to mortality in this population. This observational, multicenter, prospective study was conducted using data from a well-characterized Spanish cohort of patients with SjD. SIRs were calculated using data from the National Cancer Registry, and independent predictors of lymphoma were identified through multivariate Cox regression models. The RR was employed to assess the impact of lymphoma on mortality. A total of 314 patients with SjD were followed for a median of 9.5 years (range: 9.2-9.9). Eleven patients (3.5%) developed NHL, resulting in an SIR of 15.36 (95% CI: 15.32-15.40) compared to the general population. Cryoglobulinemia was identified as the strongest independent predictor of lymphoma (HR: 11.07; 95% CI: 1.18-103.75).Patients with SjD face a markedly elevated risk of NHL, primarily driven by cryoglobulinemia. These findings underscore the need for vigilant risk stratification, early detection, and tailored interventions to reduce lymphoma-related mortality in this population. Future studies should validate these results in diverse cohorts and explore targeted therapeutic strategies.
Indexed as
Identifiers
40767878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.